Needham Reiterates Buy on Esperion Therapeutics, Maintains $9 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a 'Buy' rating on Esperion Therapeutics (NASDAQ:ESPR) and maintained a $9 price target.
October 02, 2023 | 10:31 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Esperion Therapeutics has received a reiterated 'Buy' rating from Needham analyst Serge Belanger, with a maintained price target of $9.
The reiterated 'Buy' rating and maintained price target by Needham analyst Serge Belanger indicates a positive outlook for Esperion Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100